Scinai revenue reaches $949 thousand in H1

• Scinai Immunotherapeutics reported first-half 2026 revenue of $949 thousand, up from $773 thousand a year earlier.
• The company reported a net income of $1.6 million, mainly due to a $6.4 million bargain purchase gain from the Recipharm Israel acquisition.
• Scinai stated that committed CDMO customer orders reached approximately $3.1 million as of August 16, 2026.

Scinai Immunotherapeutics (NASDAQ:SCNI) reported first-half 2026 revenue of $949 thousand, up from $773 thousand a year earlier, driven mainly by its acquired Yavne contract development and manufacturing organization operations.

The company’s cost of revenues increased to $3.3 million, resulting in a gross loss of $2.4 million, while revenue growth reflected contributions from the CDMO business.

Operating loss widened to $4.6 million, while net income reached $1.6 million compared with a $4.1 million loss in the prior-year period, mainly due to a $6.4 million bargain purchase gain from the Recipharm Israel acquisition.

Scinai stated that committed CDMO customer orders totaled approximately $3.1 million as of August 16, 2026.

The company reported that about $2.1 million of committed CDMO orders had been invoiced, with approximately $650 thousand received for an expanded U.S. clinical manufacturing program.

Scinai Immunotherapeutics operates a biotechnology business and CDMO platform focused on supporting pharmaceutical development and manufacturing programs following its acquisition of Recipharm Israel operations.